Views 2,905
Citations 0
From The Medical Letter on Drugs and Therapeutics
June 2, 2015

An Inhaled Insulin (Afrezza)

Author Affiliations

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;313(21):2176-2177. doi:10.1001/jama.2015.5634

The FDA has approved an inhaled, rapid-acting, dry-powder formulation of recombinant human insulin (Afrezza–Mannkind/Sanofi) for treatment of adults with type 1 or type 2 diabetes. In patients with type 1 diabetes, the drug must be used in combination with long-acting insulin. Another inhaled, rapid-acting insulin (Exubera) was approved in 2006 for the same indication, but was withdrawn from the market the following year.1

First Page Preview View Large
First page PDF preview
First page PDF preview